Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Fresenius SE KGaAXSWX:FRE 68 EV-to-Revenue is 1.61 as of Aug. 14, 2026, which is 2% below its 10-year median of 1.64. GuruFocus rates XSWX:FRE with a GF Score™ of 68/100 and a GF Value™ of CHF37.20 (Modestly Overvalued). The stock has 5 warning signs investors should review. Among 665 Healthcare Providers & Services companies, Fresenius SE KGaA ranks better than 55.49% on this metric.
EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Fresenius SE KGaA's enterprise value is CHF34,758 Mil.
Fresenius SE KGaA's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 was CHF21,639 Mil. Therefore, Fresenius SE KGaA's EV-to-Revenue for today is 1.61.
The historical rank and industry rank for Fresenius SE KGaA's EV-to-Revenue or its related term are showing as below:
XSWX:FRE'
s EV-to-Revenue Range Over the Past 10 Years
Min: 1.26 Med: 1.64 Max: 2.49
Current: 1.58
During the past 13 years, the highest EV-to-Revenue of Fresenius SE KGaA was 2.49. The lowest was 1.26. And the median was 1.64.
XSWX:FRE's EV-to-Revenue is ranked better than 55.49% of 665
companies
in the Healthcare Providers & Services industry
Industry Median: 1.81
vs XSWX:FRE: 1.58
As of today (2026-08-14), Fresenius SE KGaA's stock price is CHF44.36.
Fresenius SE KGaA's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was CHF38.58. Therefore, Fresenius SE KGaA's PS Ratio for today is 1.15.
Fresenius SE KGaA's share price for today is CHF44.36.
Fresenius SE KGaA's Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF38.58.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA EV-to-Revenue Related Terms
Fresenius SE KGaA EV-to-Revenue Historical Data
* Premium members only.
The historical data trend for Fresenius SE KGaA's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XSWX:FRE vs HCA, THC, DVA: EV-to-Revenue Comparison
For the Medical Care Facilities subindustry, Fresenius SE KGaA's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Fresenius SE KGaA EV-to-Revenue vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Fresenius SE KGaA's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Fresenius SE KGaA's EV-to-Revenue falls into.
Fresenius SE KGaA's current Enterprise Value is CHF34,758 Mil.
Fresenius SE KGaA's Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF21,639 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Fresenius SE KGaA (XSWX:FRE) has a EV-to-Revenue of 1.61 as of Aug. 14, 2026. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Fresenius SE KGaA and its competitors. This is near median its historical median of 1.64. Over the past decade, Fresenius SE KGaA's EV-to-Revenue has ranged from 1.26 to 2.49. According to the industry distribution chart, Fresenius SE KGaA ranks #296 out of 665 companies in the Healthcare Providers & Services industry, placing it in the top 44.5%.
Is Fresenius SE KGaA's EV-to-Revenue too high?
Fresenius SE KGaA's current EV-to-Revenue of 1.61 is near median its 10-year median of 1.64. Over the past 10 years, this metric has ranged from a low of 1.26 to a high of 2.49. The Healthcare Providers & Services industry median EV-to-Revenue is 1.81. Fresenius SE KGaA's value of 1.61 is 11% below this industry median. Based on the distribution chart, Fresenius SE KGaA ranks #296 out of 665 companies in the Healthcare Providers & Services industry, which is above the industry midpoint. Overall, Fresenius SE KGaA has a GF Score™ of 68/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fresenius SE KGaA's EV-to-Revenue compare to HCA and THC?
According to the Healthcare Providers & Services industry distribution chart, Fresenius SE KGaA ranks #296 out of 665 companies for EV-to-Revenue. This puts Fresenius SE KGaA in the upper half of its industry. The industry median EV-to-Revenue is 1.81. Fresenius SE KGaA's value of 1.61 is 11% below this benchmark. Historically, Fresenius SE KGaA's own EV-to-Revenue has ranged from 1.26 to 2.49 over the past decade. While the company's 10-year median is 1.64 vs. the industry median of 1.81, Fresenius SE KGaA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-Revenue for a Healthcare Providers & Services company?
The median EV-to-Revenue among Healthcare Providers & Services companies is 1.81, based on 665 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-Revenue significantly above this median, while those in the bottom quartile fall well below. However, EV-to-Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Fresenius SE KGaA's current EV-to-Revenue of 1.61 is 11% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-Revenue mean?
A high EV-to-Revenue can signal that a stock is expensive relative to its fundamentals. EV to Revenue ratio is the company's enterprise value divided by sales. View historical data on Fresenius SE KGaA and its competitors. For the Healthcare Providers & Services industry, the median EV-to-Revenue is 1.81 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Fresenius SE KGaA's current EV-to-Revenue is 1.61, which is near median its own 10-year median of 1.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fresenius SE KGaA stock overvalued right now?
Based on GuruFocus' analysis, Fresenius SE KGaA (XSWX:FRE) is currently considered Modestly Overvalued. The stock's GF Value™ is CHF37.20, compared to a current price of CHF44.36 — trading 19.2% above its estimated fair value. The current EV-to-Revenue is 1.61, which is near median its 10-year median of 1.64 and 11% below the Healthcare Providers & Services industry median of 1.81. Fresenius SE KGaA's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-Revenue calculated?
EV-to-Revenue is calculated from a company's financial statements. For Fresenius SE KGaA (XSWX:FRE), the current EV-to-Revenue is 1.61 as of Aug. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Fresenius SE KGaA (XSWX:FRE) Overvalued in 2026?
Based on GuruFocus' analysis, Fresenius SE KGaA stock appears to be overvalued.
The current stock price of CHF44.36 is trading 19.2% above its estimated GF Value™ of CHF37.20.
GuruFocus considers Fresenius SE KGaA to be Modestly Overvalued.
Key valuation signals for XSWX:FRE:
EV-to-Revenue: 1.61 (near median its 10-year median of 1.64)
GF Value™: CHF37.20 vs. price of CHF44.36 (19.2% above fair value)
Industry Position: 11% below the Healthcare Providers & Services median (#296 of 665)
No single metric tells the full story. See the XSWX:FRE stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Fresenius is a healthcare holding company based in Germany. The company owns a minority stake in dialysis service provider and equipment manufacturer Fresenius Medical Care. The Kabi segment manufactures intravenous drugs, nutrition products, infusion and transfusion therapies, and related pumps. The Helios segment operates private hospitals primarily in Germany and Spain.
68GF Score
Get the complete analysis for XSWX:FRE
EV-to-Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:FRE has been successfully added to your 
